Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol’s Fibrotic Game Plan: Promedior Acquisition Hinges On Phase II Results

This article was originally published in The Pink Sheet Daily

Executive Summary

Bristol’s third deal in anti-fibrosis field in past year could give it intravenous, disease-modifying candidate for myelofibrosis and idiopathic fibrosis.

You may also be interested in...



Biopharma Quarterly Dealmaking Statistics, Q3 2015

Biopharma financing totaled $9.7 billion, almost half from follow-on public offerings; there was big consolidation in the generics and health services industries. AstraZeneca signed a dozen partnerships, many of which focused on oncology.

Deal Watch: Bristol Continues Push Into Fibrotic Disease Area

Novartis and Amgen exchange rights around CNS candidates in Alzheimer’s and migraine. AstraZeneca out-licenses global rights, except for Japan and Asia, for Phase III psoriasis candidate brodalumab to Valeant.

$21.5 Million Series D Round Gives Promedior Runway To Advance Lead Program In Two Fibrotic Indications

Recent deal-making has brought larger, deeper-pocketed players into the IPF space, but Promedior still likes its approach of going it alone with Pentraxin-2-based therapies in fibrotic disease.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS078868

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel